GlaxoSmithKline: Pipeline , Products , Performance , Potential

Publication Date	February 2008
Publisher	Espicom
Product Type	Report
Pages	300
ISBN Number	not applicable
Product Code	ESP00114

Price

£595.00
approximately: $884 | €700

PDF

Order above formats by FAX

Summary

Headquartered in the UK, GlaxoSmithKline was formed in 2000 as a result of the merger of Glaxo Wellcome and SmithKline Beecham. It employs over 100,000 people in 116 countries with over 15,000 involved in research. GSK has a broad portfolio, with projects in the fields of respiratory, central nervous system, anti-infectives, metabolic disorders, oncology, cardiovascular and urogenital. In addition, GSK has an extensive vaccines portfolio. According to GSK, it supplied one quarter of the world's vaccines by the end of 2006 and had a further 20 in clinical development.

According to GSK, the key drivers of its business performance are growth of existing products and the launch of new products. The group had 12 products with over 500 million in annual global sales in 2007 and the strong growth seen from key products such as Seretide/Advair and GSK's vaccines business is expected to continue in the short term. However, GSK has already seen the significant impact of generic competition on products such as Paxil IR and Wellbutrin SR, which were both adversely affected following the arrival of generics in the US in 2003 and 2004. Within our forecast period to 2012, for the majority of GSK's therapeutic areas, most of its major products are forecast to show sales declines, mainly due to generic competition.

As GSK braces itself for intensifying generic drug competition it faces further disappointing sales from its pivotal diabetes treatment, Avandia. In addition, GSK has lost out to Merck & Co in the race to launch its cervical cancer vaccine, Cervarix. Merck has already won contracts across much of the EU for Gardasil, which it markets in Europe through a joint venture with sanofi-aventis. It has currently been approved in 85 countries, including the US. GSK however, only received European regulatory approval for Cervarix in September 2007 and, contrary to the anticipated US approval, in December 2007 the FDA issued a request for further information. GSK may be convinced of the merits of Cervarix and has funded a head-to-head trial comparing the two vaccines, with preliminary results due to be published in summer 2008, but the accumulating delay in approval has given Merck a head start which may be difficult to counter.

In response to these problems, GSK is implementing a restructuring which is designed to cut costs by 350 million in 2008 and 700 million annually from 2010. This will include the closure of a number of factories and several thousand job cuts from the worldwide workforce. The company also intends to reduce the number of sales representatives. Sales and other administrative expenses are expected to decline to less than 30 per cent.

Content

Latest Results
Executive Summary
- Introduction
- Financial Performance 2007
- Divisional Performance
- Geographic Performance
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Discontinued Agreements
- Production
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Discontinued Projects
- Conclusions
Therapeutic Area Focus
R&d Pipeline
Respiratory
- Marketed Products
- Flixonase/Flonase
- Flixotide/Flovent
- Seretide/Advair
- Serevent
- Veramyst/Allermist/Avamys
- R&d Projects
- 1004723
- 1160724
- 159797 (Td-3327)
- 159802
- 2190914
- 256066
- 573719
- 597901
- 642444
- 656933
- 679586
- 681323
- 835726
- 856553
- 870086
- 923295
- 961081
- Ariflo
- Darotropium
- Growth Forecast
Neurosciences
- Marketed Products
- Imigran/Imitrex
- Lamictal
- Requip/Adartel
- Seroxat/Paxil
- Wellbutrin
- Zyban
- R&d Projects
- 1014802
- 1018921
- 163090
- 1838262
- 189254
- 239512
- 249320
- 372475
- 424887
- 468816
- 561679
- 598809
- 618334
- 649868
- 729327
- 742457
- 773812
- 823296
- 842166
- 856553
- 876008
- 933776
- Firategrast
- Gepirone Er
- Lunivia
- Talnetant (223412)
- Growth Forecast
Antivirals
- Marketed Products
- Agenerase
- Combivir
- Epivir
- Epzicom/Kivexa
- Lexiva
- Relenza
- Retrovir
- Trizivir
- Valtrex/Zelitrex
- Zeffix/Heptovir/Epivir-Hbv
- Ziagen
- Zovirax
- R&d Projects
- 1349572
- Growth Forecast
Vaccines
- Glaxosmithkline
- Marketed Products
- Paediatric Vaccines
- Infanrix/Pediarix
- Priorix
- Rotarix
- Other Vaccines
- Boostrix
- Cervarix
- Fluarix
- Flulaval/Fluviral
- Hepatitis Vaccines
- Menitorix
- R&d Projects
- Paediatric Vaccines
- Hib-Mency-Tt
- Menacwy-Tt
- Mtb72f/As02a
- Infanrix-Ipv
- Synflorix
- Other Vaccines
- Cytomegalovirus Vaccine
- Daronrix
- Dengue Fever Vaccine
- Epstein Barr Virus Vaccine
- Flu Improved
- Prepandrix
- Hepatitis E Vaccine (Gle438; Gl438)
- Hiv Vaccine
- Mosquirix
- Simplirix
- Streptococcus Pneumoniae Vaccine
- Tuberculosis Vaccine
- Varicella Zoster Vaccine
- Pharmaccines
- Mage-A3
- P501
- Growth Forecast
Cardiovascular
- Marketed Products
- Arixtra
- Coreg
- Others
- R&d Projects
- 256073
- 856553
- Volibris
- Darapladib
- Rilapladib
- Growth Forecast
Urogenital
- Marketed Products
- Avodart
- Levitra
- Others
- R&d Projects
- Solabegron
- Growth Forecast
Metabolic
- Marketed Products
- Avandia
- Bonviva/Boniva
- R&d Projects
- 376501
- 756050
- Albiglutide (716155)
- Otelixizumab
- Renoglifozin Etabonate
- Growth Forecast
Antibacterials/Antimalarials
- Marketed Products
- Altabax/Altargo
- Augmentin
- Lapdap
- Zinnat/Ceftin
- R&d Projects
- 580416
- 945237
- Etaquine
- Farglitazar
- Sitamaquine
- Growth Forecast
Oncology and Emesis
- Marketed Products
- Atriance/Arranon
- Hycamtin
- Tykerb
- Zofran
- R&d Projects
- 1363089
- 461364
- 690693
- Armala
- Elesclomal
- Gsk-923295
- Humax-Cd20
- Mapatumumab
- Promacta
- Rezonic
- Totrombopag
- Growth Forecast
Gastrointestinal
- Marketed Products
- Glaxosmithkline
- Zantac
- Others
- R&d Projects
- 962040
- Entereg
- Solabegron
- Growth Forecast
Musculoskeletal & Inflammation
- R&d Projects
- 1827771
- 221149
- 232802
- 274150
- 315234
- 768974
- 856553
- 971086
- Bosatria
- Ccx354
- Lymphostat-B
- Op-R003
- Ronacaleret
- Growth Forecast
Appendix 1 - Financial Performance
- Full Year Results 2007
Appendix 2 - Key Agreements
- Adolor Corporation
- Aeras Global Tb Vaccine Foundation
- Amira Pharmaceuticals
- Anacor Pharmaceuticals Inc
- Antigenics Inc
- Apotex
- Aphton Corporation
- Arana Therapeutics Ltd
- Asahi Chemical Industry Co
- Astellas Pharma
- Astex Therapeutics Ltd
- Astrazeneca
- Avant Immunotherapeutics Inc
- Bayer
- Biomrieux-Pierre Fabre
- Biovail Corporation International
- Biowa Inc
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Coley Pharmaceutical Group
- Chemocentryx
- Crucell Nv/Walter Reed Army Institute of
- Research
- Cytokinetics Inc
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Epix Pharmaceuticals
- Eurand Nv
- Eusa Pharma
- Exelixis Inc
- Fabre-Kramer Pharmaceuticals Inc
- Galapagos Nv
- Gilead Sciences Inc
- Genmab
- Human Genome Sciences Inc (Hgs)
- Institut Pasteur
- Japan Tobacco
- Kissei Pharmaceutical
- Ludwig Institute for Cancer Research (Licr)
- Medimmune Inc
- Merck & Co
- Millennium Pharmaceuticals Inc
- Mitsubishi Tanabe Pharma
- Neurocrine Biosciences Inc
- Neurosearch A/S
- Nikem Research Srl
- North American Department of Health and
- Human Services
- Novo Nordisk
- Nps Pharmaceuticals Inc
- Oncomed Pharmaceuticals Inc
- Organon
- Pharmacopeia Inc
- Pozen Inc
- Ranbaxy Laboratories Limited
- Roche
- Santaris Pharma as
- Santarus Inc
- Sepracor Inc
- Shionogi
- Sinovac Biotech Ltd
- Sirna Therapeutics Inc
- Skyepharma Plc
- Synta Pharmaceuticals Corp
- Targacept Inc
- Teva Pharmaceutical Industries Ltd
- The International Aids Vaccine Initiative (Iavi)
- The Malaria Vaccine Initiative (Mvi) at Program
- for Appropriate Technology in Health (Path)
- The Wellcome Trust / Institute of Cancer
- Research
- Theravance Inc
- Tolerx Inc
- United Kingdom Government
- Unigene Laboratories Inc
- University of California, San Francisco
- Glaxosmithkline
- (Ucsf)/Medicines for Malaria Venture (Mmv)
- Vertex Pharmaceuticals Inc
- Vitae Pharmaceuticals Inc
- World Health Organization (Who)
- Xenoport Inc
Appendix 3 - Infrastructure
- Research and Development Facilities
- Manufacturing Facilities/Supply Chain
Appendix 4 - Key Pharmaceutical
Subsidiaries/Joint Ventures
- Subsidiaries
- Joint Ventures
Index
Index of Tables
- Principal Operating Results
- Operating Income by Business Area
- Operating Income by Business Area
- Capital Expenditure by Business Area
- Capital Expenditure by Business Area, 2007
- Capital Expenditure by Geographic Area
- Capital Expenditure by Geographic Area, 2007
- Research & Development Expenditure by Business Area
- R&d Expenditure by Business Area
- Sales by Business Area
- Pharma Sales by Therapeutic Area
- Operating Income by Business Area
- Operating Income by Business Area
- Total Assets by Business Area
- Company Sales by Destination
- Company Sales by Origin
- Pharmaceutical Sales by Destination
- Total Assets by Geographical Area
- Employees by Geographical Area
- Employees by Geographical Area, 2007
- Employees by Function
- Employees by Function
- Recent Product Approvals
- Major Products, Therapeutic Areas and Sales
- Major Respiratory Products, 2007
- Major Neurosciences Products, 2007
- Major Antiviral Products, 2007
- Major Vaccines Products, 2007
- Major Cardiovascular Products, 2007
- Major Urogenital Products, 2007
- Major Metabolic Products, 2007
- Major Antibacterial Products, 2007
- Major Oncology and Emesis Products, 2007
Index of Charts
- Sales by Business Area
- Breakdown of Pharma Sales by Therapeutic Area, 2007
- Company Sales by Destination
- Company Sales by Origin
- Pharmaceutical Sales by Destination
- Sales of Top 30 Products (2001a-2012e)
- Top Selling Products, 2007
- Major Respiratory Products, 2007
- Flixonase/Flonase Sales (2002a-2012e)
- Flixotide/Flovent Sales (2002a-2012e)
- Seretide/Advair Sales (2002a-2012e)
- Serevent Sales (2002a-2012e)
- Veramyst/Allermist/Avamys Sales (2008e-2012e)
- Airflo Sales (2002e-2012e)
- Sales of Major Neurosciences Products, 2007
- Imigran/Imitrex Sales (2002a-2012e)
- Lamictal Sales (2002a-2012e)
- Requip/Adartel Sales (2002a-2012e)
- Seroxat/Paxil Sales (2002a-2012e)
- Wellbutrin Sales (2002a-2012e)
- Sale of Major Antiviral Products, 2007
- Agenerase/Lexiva Sales (2002a-2012e)
- Combivir Sales (2002a-2012e)
- Epivir Sales (2002a-2012e)
- Epzicom/Kivexa Sales (2002a-2012e)
- Lexiva/Agenerase Sales (2002a-2012e)
- Relenza Sales (2002a-2012e)
- Trizivir Sales (2002a-2012e)
- Valtrex/Zelitrex Sales (2002a-2012e)
- Zeffix Sales (2002a-2012e)
- Ziagen Sales (2002a-2012e)
- Zovirax Sales (2002a-2012e)
- Sales of Major Vaccines, 2007
- Infanrix Sales (2002a-2012e)
- Cervarix Sales (2002e-2012e)
- Major Cardiovascular Products, 2007
- Arixtra Sales (2002a-2012e)
- Coreg Sales (2002a-2012e)
- Ambrisentan Sales (2008e-2012e)
- Major Urogenital Products, 2007
- Avodart/Avolve Sales (2002a-2012e)
- Major Metabolic Products, 2007
- Avandia/Avandamet/Avandaryl Sales (2002a-2012e)
- Bonviva/Boniva Sales (2002a-2012e)
- Major Antibacterial Products, 2007
- Augmentin Sales (2002a-2012e)
- Major Oncology and Emesis Products, 2007
- Hycamtin Sales (2002a-2012e)
- Zofran Sales (2002a-2012e)
- Glaxosmithkline
- Humax CD-20 Sales (2008e-2012e)
- Zantac Sales (2002a-2012e)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&d Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity